A solid-phase radioimmunoassay, applying whole Mycobacterium leprae as antigen and radiolabeled protein A from Staphylococcus aureus as antibodydetecting reagent, was used for the determination of specific immunoglobulin G (IgG) 
A solid-phase radioimmunoassay, applying whole Mycobacterium leprae as antigen and radiolabeled protein A from Staphylococcus aureus as antibodydetecting reagent, was used for the determination of specific immunoglobulin G (IgG) and IgM antibody responses in leprosy patients. High IgG anti-M. leprae antibody levels were found in lepromatous leprosy patients, whereas the antibody response in tuberculoid leprosy patients varied from negative, i.e., comparable with responses measured in normal individuals, to strongly positive. In tuberculoid leprosy patients, a significant increase in IgG anti-M. leprae antibody levels was observed in the more widespread forms of the disease, but positive antibody responses were especially predominant among patients with active lesions. Lepromatous leprosy patients generally demonstrated high levels of both IgG and IgM antiM. leprae antibodies, but no relation was found between the antibody responses and bacillary load or other clinical parameters. A marked decrease in specific IgG and IgM antibody levels was observed in lepromatous leprosy patients during their first year of treatment. Differences in mechanisms regulating the humoral immune response in tuberculoid and lepromatous leprosy patients were indicated, and the application of antibody assessments in leprosy control programs is discussed.
Immunological resistance to infection with Mycobacterium leprae and other obligate intracellular parasites is primarily dependent on mechanisms of cell-mediated immunity (32) . The role of the humoral immune response in leprosy and especially its influence on the host's defense have not been defined. In general, high levels of antimycobacterial antibodies are found only in patients with the disseminated, multibacillary infection (lepromatous leprosy), although occasionally a strong antibody response may be associated with tuberculoid leprosy, the localized, paucibacillary form of the disease (1, 3, 11, 20, 29) . After chemotherapy, a decrease in antibody levels has been demonstrated in both lepromatous and tuberculoid leprosy patients (19, 21, 33) , whereas an increase in serum antibody activity has been noted in relapsed tuberculoid leprosy patients (33). These findings indicate the usefulness of antibody assessments in leprosy control programs, but much better descriptions of the classes and specificities of the anti-M. leprae antibodies are needed. It is especially important to correlate the presence or absence of those antibodies with the various clinical manifestations of the disease, particularly in the tuberculoid region of the spectrum. Definition of these features will allow a judgement as to whether serial antibody assessments can provide information on the prognosis of the disease.
In this paper, three solid-phase radioimmunoassays for the quantitation of anti-M. leprae antibodies are described. In the first assay, human serum was incubated with whole M. leprae bacilli which were immobilized on the wells of a polyvinyl microtiter plate, and bound antibodies were detected with 125I-labeled protein A from Staphylococcus aureus. In the second assay, an incubation with rabbit anti-human immunoglobulin G (IgG) antiserum was inserted to amplify the sensitivity of the assay. Third, a modification was presented for the detection of IgM antibodies reacting with M. leprae. These solid-phase radioimmunoassays were used for the quantitation of anti-M. leprae antibodies in sera from normal individuals and leprosy patients across the clinicohistopathological spectrum of the disease. The antibody levels were correlated with the various disease symptoms, and the effect of chemotherapy on the anti-M. leprae antibody response was assessed in lepromatous leprosy patients.
MATERIALS AND METHODS Sera. Sera were obtained from leprosy patients attending the clinics of the All Africa Leprosy and Rehabilitation Training Centre, Addis Ababa, Ethiopia. Unless otherwise stated, the patients had not received any previous anti-leprosy treatment. Diagnosis and classification of leprosy were done by clinical and histological examinations (22, 23) . As controls, sera from healthy individuals of similar ethnic and socioeconomic backgrounds were included. From 15 lepromatous leprosy patients, serum was collected at the start of treatment with 100 mg of diaminodiphenyl sulfone (DDS) daily, after 2 to 4 months of treatment, and after 10 to 14 months of treatment. All serum samples were stored at -20'C until use. To minimize interassay variations, sera from different groups of patients were assayed in one experiment.
A positive reference serum pool was prepared by pooling 15 sera of patients with lepromatous leprosy, and a negative reference serum pool was prepared by combining 8 sera from healthy individuals living in Norway.
Antigens. Freeze-dried, armadillo-derived M. leprae bacilli (batch AB40) were provided by R. J. W. Rees antigen-coated plates were used for the three types of radioimmunoassays described below.
(i) Direct assay. The coated plates were washed twice with PBST, and 150 ,ul of serum (dilutions of 1:100 and 1:1,000 in RIA buffer) was added. The plates were incubated overnight at 4°C. Unbound antibody was removed by three washings with PBST. Radiolabeled protein A (100 ,u1 containing 125,000 cpm), diluted in RIA buffer, was added, and after an incubation of 6 h at room temperature, the plates were washed three times with PBST and air dried. The wells were cut off, and bound radioactivity was measured in a gamma counter (1270 Rackgamma II; LKB, Turku, Finland).
(ii) Indirect assay for IgG antibodies. Amounts (150 ,ud) of serum diluted 1:1,000 and 1:10,000 in RIA buffer were placed into antigen-coated wells and left overnight at 4°C. After the plates were washed with PBST, 150 p1 of a 1:200 dilution of rabbit anti-human IgG antiserum (DAKO immunoglobulins A/S, Copenhagen, Denmark) in RIA buffer was added, and the plates were incubated for 5 h. After three washings with PBST, 100 ,u1 of protein A (125,000 cpm) was added and incubated for 6 h. Bound radioactivity was determined as described above.
(Uii) Indirect assay for IgM antibodies. All sera were adsorbed first with Staphylococcus aureus Cowan type I, which was kindly provided by G. Kronvall, Department of Medical Microbiology, University of Lund, Sweden. The bacteria were grown on CCY medium and, after harvest, were heat killed, Formalin treated, and stored at 4°C as a 10% suspension in phosphate-buffered saline containing 0.05 M NaN3 (15) . Before use, the staphylococci were washed twice with PBST and adjusted to a 5% (vol/vol) suspension in PBST. For the adsorption of sera, aliquots (1 ml) were centrifuged at 2,000 x g for 30 min in plastic conical tubes (no. 72.690; Sarstedt, Nuembrecht, West Germany) giving a bacterial pellet of 50 pI. The supernatant was discarded, and 500 ,ul of test serum, diluted 1:100 in RIA buffer, was added. After suspending the bacteria by using a Vortex mixer, the suspension was incubated for 2 h at room temperature. The supernatant obtained after centrifugation at 2,000 x g for 45 min was assayed for antibody activity. Amounts (150 ,ul) of the supernatant were pipetted into an antigen-coated well and left overnight at 4°C. The unbound antibody was washed off with PBST, and 150 ,ul of a 1:200 dilution of rabbit anti-human IgM antiserum (DAKO immunoglobulins A/S) was added. After an incubation of 5 h at room temperature, the plates were washed three times with PBST and incubated with protein A (125,000 cpm). Bound radioactivity was determined as described above. (27) .
RESULTS
Radioimmunoassay conditions. The binding curves for the positive reference serum pool, obtained in the direct assay with increasing amounts of M. leprae fixed to the wells, are shown in Fig. 1 . With the negative reference serum pool at a 1:100 dilution, the radioactivity bound to the wells increased from 958 to 1,505 cpm. A dose of 2 pg of M. leprae was chosen for routine use because it was sufficient for an excellent discrimination between the positive and negative reference serum pools and conserved the limited supply of antigenic material available. By using this concentration of M. leprae and a 1:100 dilution of the positive refer- ence serum pool, the addition of 125I-protein A giving 125,000 cpm resulted in apparent saturation of protein A binding sites (data not shown). Figure 2 shows the standard binding curves obtained in the direct assay, the indirect assay for IgG antibodies, and the indirect assay for IgM antibodies reacting with M. leprae. Back ground values measured as the amount of radioactivity bound when the incubation with human serum was omitted, reached 200 cpm in the direct assay and 1,500 cpm in the indirect assay. In the indirect assay for IgM antibodies, omission of the incubation with rabbit anti-human IgM antiserum served as a control for the effectiveness of the absorption procedure, and the resulting amount of bound radioactivity did not exceed the background values.
In each experiment, dilution series of the positive and negative reference serum pools were included. In 10 separate experiments, the coefficient of variation was 3.8% in the direct assay, using a 1:100 dilution of the positive reference serum pool, which indicated good reproducibility between experiments. A coefficient of variation of around 4.5% was calculated for the other radioimmunoassays.
Anti-M. leprae antibody profile in leprosy patients and normal controls. The antibody activity directed against M. leprae in sera from leprosy patients categorized according to their clinicohistopathological classification was compared with the antibody activity present in sera from normal individuals. The results obtained with the direct assay and expressed as percent cpm of the positive reference are shown in Fig. 3 . In general, the method of evaluating the results, either as percent cpm or as percent activity of the positive reference, did not alter the antibody profile across the disease spectrum. However, as may be anticipated from the standard binding curves, the individual samples with a low or high percent cpm tended to give respectively lower or higher values when expressed as percent activity.
The sera from normal individuals contained little anti-M. leprae antibody activity (4.3 + 3.8% cpm). By setting the minimum positive antibody activity at the mean value of the normal group plus two standard deviations of the mean, i.e., at 12.0% cpm, a positive antibody response could be assigned to 2 out of 31 normal individuals. Many patients classified toward the tuberculoid end of the spectrum showed an antibody response comparable to that of the normal controls. A positive response could be assigned to 3 out of 9 polar tuberculoid (TT) patients and to 16 out of 34 borderline tuberculoid (BT) leprosy patients. All of the patients classified towards the lepromatous end of the spectrum showed a positive antibody response directed against M. leprae.
The same sera tested in the direct assay at 1:100 and 1:1,000 serum dilutions were analyzed with the indirect assay for IgG antibodies at 1:1,000 and 1:10,000 serum dilutions. With the indirect assay, antibodies directed against M. leprae could be detected at a 50 to 100 times higher serum dilution than that used for the direct assay. The results with the indirect assay were similar to those obtained with the direct assay. An interassay correlation coefficient of r = 0.87 was found when the results were expressed as percent cpm of the positive reference, and r = 0.82 was found when expressed as percent activity of the positive reference. (Table   1) . When the patients were classified by the duration of disease, the positive antibody responders were mainly found in the group with a history of less than 3 years. However, it should be mentioned that the analysis on duration of disease is based on the time the patient himself observed the first signs of the disease and may thus be biased. A significant increase in antibody activity was observed in tuberculoid patients with the more widespread forms of the disease, i.e., with more than four patches or more than two affected nerves. The analysis was especially valid when the state of disease was described as either quiescent or active. No significant differences in the IgM anti-M. leprae antibody response on the basis of clinical features could be demonstrated.
Patients classified toward the lepromatous end of the spectrum were classified by their bacterial load (bacterial and morphological index), extent of nerve damage, and type of skin infiltration. Also within this group, the individual's antibody responses varied considerably, but no indication for a correlation between either IgG or IgM anti-M. leprae antibody levels and clinical signs was observed (data not shown).
Anti-M. kprae antibody response during 1 year of chemotherapy in lepromatous leprosy patients. The effect of treatment with DDS (100 mg daily) on the humoral immune response was studied in 15 lepromatous leprosy patients. Four had been classified as borderline lepromatous (BL) (no. Ieprae antibody levels determined with the direct assay.
to 9) and six as polar lepromatous (LLp) (no. 10 to 15). In all patients, 1 year of chemotherapy resulted in a marked improvement as judged by clinical and bacteriological parameters. The results from the direct assay and the indirect assay for IgM antibodies, expressed as percent activity of the positive reference, are shown in Fig. 6 and 7.
In general, 1 year of chemotherapy resulted in a significant decrease in anti-M. leprae antibody levels (P < 0.01). As a group, the mean IgG antibody activity measured with the direct assay was 124% of positive at the start of treatment and decreased to 59% at the end of the observation period. The mean value for IgM antibodies decreased from 50% activity at the beginning to 18% at the end. In most patients, the decline in antibody levels occurred gradually. Abrupt changes, as indicated by the assessments at 2 to 3 months after the start of chemotherapy, were observed in some patients, whereby a change in antibody levels of one class did not necessarily coincide with a change in the other antibody class.
DISCUSSION
This study describes a convenient solid-phase radioimmunoassay for the determination of antibodies directed against surface antigens of M. leprae. The method used for the immobilization of cells on the wells of polyvinyl microtiter plates has been applied successfully in other radiometric immunoassays (14) . During preliminary experiments, we observed a substantial difference between the antibody binding capacities of various M. leprae preparations. Humanderived M. leprae, isolated from nodules of lepromatous leprosy patients (7), also bound antibodies, but considerable batch-to-batch variations were observed. The M. leprae bacilli used (12, 17, 24) , but its binding to polyclonal IgM and IgA may be minimal (18, 25 With the solid-phase radioimmunoassay, the levels of IgG antibodies directed against M. Ieprae were determined in leprosy patients and normal controls. In general, patients classified towards the lepromatous end of the spectrum showed significantly higher antibody responses than those classified towards the tuberculoid end of the disease spectrum. Since high levels of antimycobacterial antibodies have been found mainly in the multibacillary form of the disease, a clear correlation between bacterial load and humoral immune response has been suggested (20) . Indeed, reducing the bacterial load by chemotherapy seems to affect the amount of circulating antibodies in the majority of lepromatous leprosy patients (19, 21) . Similar observations have been made in tuberculoid leprosy patients (33). However, the antibody levels vary greatly even within the classified groups, and, in patients classified towards the lepromatous end of the spectrum, the level of circulating antibodies directed against M. leprae could not be related with the bacterial load assessed by skin smears or other clinical signs. In these highly disseminated infections, the mechanisms regulating the antibody response may be very complex because of the continuous presence of antigenic material. In addition, the specificity of the antibody response may be questioned. M. tuberculosis and its purified protein derivative have demonstrated the ability to induce polyclonal antibody production in vitro (4, 8) . Since M. leprae and M. tuberculosis are closely related (31) , similar in vivo mechanisms may contribute to the observed variations in antibody responses in the multibacillary infection.
In tuberculoid leprosy patients, the IgG anti-M. leprae antibody levels appeared to be associated with the extent and activity of the disease. Clearly, the more widely disseminated tuberculoid infections have, or have had, a larger number of bacilli. In these patients, the stimulation of antibody synthesis, for example, by circulating antigens triggering antibody production in the central lymphon compartment (28) , is more likely to occur.
The association of high antibody levels with the state of disease activity in tuberculoid leprosy was even more highly significant than the association with the degree of dissemination. The clinical phenomena which accompany the active phase may be attributed to delayed-type hypersensitivity reactions (7) , and the increased antibody levels may be explained by a simultaneous increased level of helper T-cell activity (5) . On the other hand, the disease activity may be associated with the first phases of dissemination when the disease changes from a localized to a systemic infection. The concomitant change in antigen presentation to the lymphoid system may contribute to the appearance of delayedtype hypersensitivity reactions.
The suggested distinction between mechanisms regulating the antibody response in tuberculoid and lepromatous leprosy is further confirmed when the IgM anti-M. leprae antibody responses are analyzed. Some tuberculoid antibody patients mounted a strong IgG anti-M. leprae antibody response, but their IgM anti-M. leprae responses were always low compared with those of lepromatous leprosy patients. Two tuberculoid leprosy patients showed a positive IgM and a negative IgG anti-M. leprae antibody response. Presumably, these patients were assessed during the first stages of antibody production, whereas in the other tuberculoid leprosy patients, the proportion of the antibody responses of both classes resembles a normal antibody synthesis pattern.
Nearly all lepromatous leprosy patients were positive IgM anti-M. leprae antibody responders, which may be interpreted as a sign of a persistent infection, analogous for example, to the presence of specific IgM antibodies in measles during latent infection of the brain (30) . Accordingly, even after 1 year of chemotherapy, when most bacilli are still present (although most of them should have been killed), we could still detect a strong but decreased IgM anti-M. leprae antibody response in lepromatous leprosy patients.
For leprosy control programs, the analysis of antibody responses may be particularly useful in tuberculoid leprosy patients, in which group the majority of leprosy patients can be classified. Serial antibody assessments may provide information on the response to treatment and on the possibility of relapse (33) . In addition, it might prove useful to classify newly diagnosed tuberculoid patients as high or low antibody responders, on which basis different treatment regimens may be designed. The observed relation among antibody responses, the extent of nerve damage, and the presence of signs of activity may provide a method to define a group of tuberculoid leprosy patients who are at high risk to develop physical handicaps.
